<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613349</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A02019-30</org_study_id>
    <nct_id>NCT04613349</nct_id>
  </id_info>
  <brief_title>FArial NErf MRI in the Preoperative Assessment of PArotide Tumors</brief_title>
  <acronym>NEFAPA</acronym>
  <official_title>FArial NErf MRI in the Preoperative Assessment of PArotide Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. st visit: Inclusion, 3Tesla injected parotid MRI performed as part of routine care for&#xD;
           characterization, to which two specific high resolution sequences will be added.&#xD;
           Evaluation of the exact position of the parotid tumor relative to the trunk of the&#xD;
           facial nerve and its first branches, classification into two categories: on contact (≤ 5&#xD;
           mm) or at a distance (&gt; 5 mm).&#xD;
&#xD;
        2. nd visit: Surgical intervention of the parotid tumor. The surgeon will specify the same&#xD;
           data as that collected by the radiologists after the MRI.&#xD;
&#xD;
        3. rd visit: Post-operative consultation in the week following the intervention. The&#xD;
           surgeon will look for the occurrence of post-operative facial paralysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">May 13, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>measurements by the radiologist on the high resolution 3Tesla MRI with specific sequences.</measure>
    <time_frame>day 0</time_frame>
    <description>measurements by the radiologist on the high resolution 3Tesla MRI with specific sequences.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>assessment by the surgeon during the excision surgery of the parotid lesion</measure>
    <time_frame>day 0</time_frame>
    <description>assessment by the surgeon during the excision surgery of the parotid lesion</description>
  </primary_outcome>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Parotid Tumor</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>All patients included will benefit from the two methods of evaluating the anatomical relationships between the facial nerve and the parotid tumor:&#xD;
New medical imaging technique evaluated: high-resolution 3 Tesla parotid MRI with specific sequences and gadolinium injection;&#xD;
Gold standard: Intraoperative examination.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient candidate for first line surgery for a parotid tumor&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years old&#xD;
&#xD;
          -  Patient candidate for first line surgery for a parotid tumor&#xD;
&#xD;
          -  Parotid tumor located near the trunk of the facial nerve and or its first branches of&#xD;
             division according to the clinical examination of the ENT surgeon and the imaging data&#xD;
&#xD;
          -  Affiliate or beneficiary of a social security scheme&#xD;
&#xD;
          -  Written consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personal history of parotid homolateral surgery&#xD;
&#xD;
          -  Absolute or relative contraindication to MRI&#xD;
&#xD;
          -  Known hypersensitivity to gadolinic contrast media&#xD;
&#xD;
          -  Pre or post operative period of a liver transplant&#xD;
&#xD;
          -  Patient benefiting from a legal protection measure&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Patient who has already benefited from a preoperative MRI to characterize a complete,&#xD;
             well conducted and interpretable parotid lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Amelie YAVCHITZ</last_name>
    <phone>0148036454</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adrien COLLIN</last_name>
    <phone>0148036401</phone>
    <email>acollin@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondation A De Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>a YAVCHITZ</last_name>
      <phone>0148036454</phone>
      <email>ayavchitz@for.paris</email>
    </contact>
    <investigator>
      <last_name>adrien Collin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>jean-Baptiste Lecanu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth SAUVAGET</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane HANS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 7, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parotid Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

